Prosight Management LP Boosts Vertex Pharmaceuticals Stake

Hedge fund adds 20,500 shares of biotech firm to portfolio

Mar. 14, 2026 at 11:08am

Got story updates? Submit your updates here. ›

Prosight Management LP, a Boston-based investment firm, has purchased 20,500 shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) during the third quarter, according to a recent SEC filing. The new position is valued at approximately $8.03 million and represents about 1.9% of Prosight's total portfolio.

Why it matters

Vertex Pharmaceuticals is a leading biotechnology company focused on developing treatments for serious diseases, particularly cystic fibrosis. The company's portfolio of CFTR modulators has transformed standards of care for many CF patients. Prosight's increased stake in Vertex signals the hedge fund's confidence in the biotech firm's continued growth and innovation.

The details

According to the SEC filing, Prosight Management LP bought the 20,500 shares of Vertex Pharmaceuticals during the third quarter. This new position is valued at approximately $8.03 million, making it the 21st largest holding in Prosight's portfolio. Vertex Pharmaceuticals accounts for about 1.9% of the hedge fund's total investments.

  • Prosight Management LP bought the 20,500 shares of Vertex Pharmaceuticals during the third quarter.

The players

Prosight Management LP

A Boston-based investment firm that has increased its stake in Vertex Pharmaceuticals.

Vertex Pharmaceuticals Incorporated

A Boston-based biotechnology company focused on developing treatments for serious diseases, particularly cystic fibrosis.

Got photos? Submit your photos here. ›

The takeaway

Prosight Management's increased investment in Vertex Pharmaceuticals underscores the hedge fund's confidence in the biotech firm's ability to continue innovating and growing its portfolio of transformative treatments for cystic fibrosis and other serious diseases.